Replies to post #394379 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

“BRILACIDIN [...] HAS A HIGH LIKELIHOOD OF REACHING COMMERCIALIZATION.”

With all the respect that’s due to Dr. Michael Zasloff, when it comes to drug development he obviously doesn’t know his ass from his elbow.

Even if IPIX had halfway reasonable management rather than the Krooked Keystone Kop kurrently in charge, its clinical history suggests it will never achieve a risk benefit ratio that would allow any regulatory authority anywhere in the world to let it onto the market.

[loanranger]

“

BRILACIDIN [...] HAS A HIGH LIKELIHOOD OF REACHING COMMERCIALIZATION.”

— Dr. Michael Zasloff

I haven't done the research required to find the source of that quote but it appeared on the IPIX website on July 14, 2017.
It may very well be an unattributed and edited excerpt from a Chapter written by Zasloff of a book published in 2015, an abstract of which follows:

"Abstract
Antimicrobial peptides of higher organisms have been studied for the past 25 years and their importance as components of innate immunity is now well established. The basic simplicity of the chemical structure of antimicrobial peptides along with the lower likelihood of the emergence of resistance compared with conventional antibiotics have made them attractive candidates for development as therapeutics. In this chapter, I describe the stories behind three drug candidates currently in clinical trials: Pexiganan, Plectasin, and Brilacidin. Each of these compounds has faced specific challenges in development and has a high likelihood of reaching commercialization. Antimicrobial peptides appear to be coming of age as therapeutics."

I wonder if Dr Zasloff feels the same way now. If you have any evidence that he does then that might be worth posting.

As far as I know Dr Z himself has never commercialized anything, including at Magainin:
"Zasloff left Penn in 1992 and joined Magainin full time.[8] He was with the company until its lead product, pexiganan, was rejected by the FDA in 1999 for lack of efficacy compared with the standard of care for diabetic foot ulcers".


https://enterininc.com/our-team-leadership-founders/